Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Innovation
Share your love
UCL-Moorfields Eye Hospital Secures £5M for Research Center
The Sir Jules Thorn Charitable Trust has allocated £5 million towards the establishment of a research center within Oriel, the collaborative initiative between UCL and Moorfields Eye Hospital aimed at advancing eye health. Partnering with Moorfields Eye Charity and Moorfields…
Toku Granted CE and UKCA Marks for CLAiR Technology
Toku announced the acquisition of the CE Mark in Europe and UKCA certification in the United Kingdom for its patented CLAiR technology. This innovation offers a non-invasive method for assessing the risk of cardiovascular disease (CVD) directly at the point…
Treatment of Intraocular Melanoma | OBN
Melanoma of the uveal tract (iris, ciliary body, and choroid), though rare, is the most common primary intraocular malignancy in adults. The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people,…
Kiora, Théa Partner for Retinal Disease Treatment
Kiora Pharmaceuticals has joined forces with Théa Open Innovation (TOI), a sister company of Laboratoires Théa, to develop and commercialize KIO-301 for the treatment of degenerative retinal diseases. The strategic agreement grants Théa exclusive worldwide development and commercialization rights, excluding…
UMass Chan Grants Gene Therapy Licenses to Iveric Bio
UMass Chan Medical School has awarded exclusive global rights for the development and commercialization of innovative adeno-associated virus (AAV) gene therapy products targeting Stargardt disease and Leber congenital amaurosis type 10 (LCA10) to Iveric Bio, an Astellas Company. While gene…
Formosa & Cristália Partner for APP13007 Rights in Brazil
Formosa Pharmaceuticals announced a strategic licensing agreement with Cristália Produtos Químicos Farmacêuticos to secure exclusive commercialization rights for APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil. APP13007 is designed for the treatment of inflammation and pain following ocular surgery and…
FDA Approves ZEISS’ VISUMAX® 800 for Nearsightedness
The FDA has approved the VISUMAX® 800 equipped with SMILE® pro software from ZEISS. This state-of-the-art femtosecond laser technology is designed for the surgical treatment of nearsightedness, with or without astigmatism. The VISUMAX® 800 enters the U.S. market at a…
UCI Secures $575K Grant for Ophthalmology Research
The University of California, Irvine School of Medicine announced the reception of a prestigious Unrestricted Grant from the esteemed nonprofit organization, Research to Prevent Blindness (RPB). The substantial grant, amounting to $575,000 over a five-year period, will be dedicated to…
Top 10 Medical Devices in Ophthalmology
Medical technology has advanced significantly in recent years, providing numerous benefits to patients and healthcare professionals. In the field of ophthalmology, innovative medical devices have been developed that have revolutionized the way eye conditions are diagnosed and treated. Here are…
Azura Ophthalmics: Phase 2 Results for AZR-MD-001
Azura Ophthalmics reported positive top-line efficacy and safety outcomes from a phase 2 investigation of AZR-MD-001 in individuals experiencing Contact Lens Discomfort (CLD) due to challenges in comfortably wearing lenses and demonstrating signs of meibomian gland dysfunction (MGD). The trial…